Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

G.V. Long; K.T. Flaherty; D. Stroyakovskiy; H. Gogas; E. Levchenko; F. de Braud; J. Larkin; C. Garbe; T. Jouary; A. Hauschild; V. Chiarion-Sileni; C. Lebbe; M. Mandalà; M. Millward; A. Arance; I. Bondarenko; J.B.A.G. Haanen; J. Hansson; J. Utikal; V. Ferraresi; P. Mohr; V. Probachai; D. Schadendorf; P. Nathan; C. Robert; A. Ribas; M.A. Davies; S.R. Lane; J.J. Legos; B. Mookerjee; J.-J. Grob

doi:10.1093/annonc/mdx176

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

G.V. Long, K.T. Flaherty, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. de Braud, J. Larkin, C. Garbe, T. Jouary, A. Hauschild, V. Chiarion-Sileni, C. Lebbe, M. Mandalà, M. Millward, A. Arance, I. Bondarenko, J.B.A.G. Haanen, J. Hansson, J. Utikal, V. FerraresiP. Mohr, V. Probachai, D. Schadendorf, P. Nathan, C. Robert, A. Ribas, M.A. Davies, S.R. Lane, J.J. Legos, B. Mookerjee, J.-J. Grob

Research output: Contribution to journal › Article › peer-review

Original language	Undefined/Unknown
Pages (from-to)	1631-1639
Number of pages	9
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	28
Issue number	7
DOIs	https://doi.org/10.1093/annonc/mdx176
Publication status	Published - 2017

Access to Document

10.1093/annonc/mdx176

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85034257560&doi=10.1093%2fannonc%2fmdx176&partnerID=40&md5=7eb8d0ca19701669675ac64b81254178

Cite this

Long, G. V., Flaherty, K. T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J. B. A. G., Hansson, J., Utikal, J., ... Grob, J-J. (2017). Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Annals of oncology : official journal of the European Society for Medical Oncology, 28(7), 1631-1639. https://doi.org/10.1093/annonc/mdx176

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. / Long, G.V.; Flaherty, K.T.; Stroyakovskiy, D.; Gogas, H.; Levchenko, E.; de Braud, F.; Larkin, J.; Garbe, C.; Jouary, T.; Hauschild, A.; Chiarion-Sileni, V.; Lebbe, C.; Mandalà, M.; Millward, M.; Arance, A.; Bondarenko, I.; Haanen, J.B.A.G.; Hansson, J.; Utikal, J.; Ferraresi, V.; Mohr, P.; Probachai, V.; Schadendorf, D.; Nathan, P.; Robert, C.; Ribas, A.; Davies, M.A.; Lane, S.R.; Legos, J.J.; Mookerjee, B.; Grob, J.-J.

In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 28, No. 7, 2017, p. 1631-1639.

Research output: Contribution to journal › Article › peer-review

Long, GV, Flaherty, KT, Stroyakovskiy, D, Gogas, H, Levchenko, E, de Braud, F, Larkin, J, Garbe, C, Jouary, T, Hauschild, A, Chiarion-Sileni, V, Lebbe, C, Mandalà, M, Millward, M, Arance, A, Bondarenko, I, Haanen, JBAG, Hansson, J, Utikal, J, Ferraresi, V, Mohr, P, Probachai, V, Schadendorf, D, Nathan, P, Robert, C, Ribas, A, Davies, MA, Lane, SR, Legos, JJ, Mookerjee, B & Grob, J-J 2017, 'Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 28, no. 7, pp. 1631-1639. https://doi.org/10.1093/annonc/mdx176

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Annals of oncology : official journal of the European Society for Medical Oncology. 2017;28(7):1631-1639. https://doi.org/10.1093/annonc/mdx176

Long, G.V. ; Flaherty, K.T. ; Stroyakovskiy, D. ; Gogas, H. ; Levchenko, E. ; de Braud, F. ; Larkin, J. ; Garbe, C. ; Jouary, T. ; Hauschild, A. ; Chiarion-Sileni, V. ; Lebbe, C. ; Mandalà, M. ; Millward, M. ; Arance, A. ; Bondarenko, I. ; Haanen, J.B.A.G. ; Hansson, J. ; Utikal, J. ; Ferraresi, V. ; Mohr, P. ; Probachai, V. ; Schadendorf, D. ; Nathan, P. ; Robert, C. ; Ribas, A. ; Davies, M.A. ; Lane, S.R. ; Legos, J.J. ; Mookerjee, B. ; Grob, J.-J. / Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2017 ; Vol. 28, No. 7. pp. 1631-1639.

@article{077bcbf0da7d4df392b1817ac1594c70,

title = "Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study",

author = "G.V. Long and K.T. Flaherty and D. Stroyakovskiy and H. Gogas and E. Levchenko and {de Braud}, F. and J. Larkin and C. Garbe and T. Jouary and A. Hauschild and V. Chiarion-Sileni and C. Lebbe and M. Mandal{\`a} and M. Millward and A. Arance and I. Bondarenko and J.B.A.G. Haanen and J. Hansson and J. Utikal and V. Ferraresi and P. Mohr and V. Probachai and D. Schadendorf and P. Nathan and C. Robert and A. Ribas and M.A. Davies and S.R. Lane and J.J. Legos and B. Mookerjee and J.-J. Grob",

note = "cited By 15",

year = "2017",

doi = "10.1093/annonc/mdx176",

language = "Non definita",

volume = "28",

pages = "1631--1639",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

number = "7",

}

TY - JOUR

T1 - Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

AU - Long, G.V.

AU - Flaherty, K.T.

AU - Stroyakovskiy, D.

AU - Gogas, H.

AU - Levchenko, E.

AU - de Braud, F.

AU - Larkin, J.

AU - Garbe, C.

AU - Jouary, T.

AU - Hauschild, A.

AU - Chiarion-Sileni, V.

AU - Lebbe, C.

AU - Mandalà, M.

AU - Millward, M.

AU - Arance, A.

AU - Bondarenko, I.

AU - Haanen, J.B.A.G.

AU - Hansson, J.

AU - Utikal, J.

AU - Ferraresi, V.

AU - Mohr, P.

AU - Probachai, V.

AU - Schadendorf, D.

AU - Nathan, P.

AU - Robert, C.

AU - Ribas, A.

AU - Davies, M.A.

AU - Lane, S.R.

AU - Legos, J.J.

AU - Mookerjee, B.

AU - Grob, J.-J.

N1 - cited By 15

PY - 2017

Y1 - 2017

U2 - 10.1093/annonc/mdx176

DO - 10.1093/annonc/mdx176

M3 - Articolo

VL - 28

SP - 1631

EP - 1639

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -